​

BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BNTX Stock Forecast

BioNTech SE stock forecast is as follows: an average price target of $127.78 (represents a 5.46% upside from BNTX’s last price of $121.16) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

BNTX Price Target

The average price target for BioNTech SE (BNTX) is $127.78 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $95.00. This represents a potential 5.46% upside from BNTX's last price of $121.16.

BNTX Analyst Ratings

Buy

According to 18 Wall Street analysts, BioNTech SE's rating consensus is 'Buy'. The analyst rating breakdown for BNTX stock is 0 'Strong Buy' (0.00%), 14 'Buy' (77.78%), 2 'Hold' (11.11%), 2 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

BioNTech SE Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2024Cory KasimovEvercore ISI$125.00$80.8054.70%3.17%
Nov 13, 2024Daina GrayboschLeerink Partners$121.00$80.8049.75%-0.13%
Nov 08, 2024Chris ShibutaniGoldman Sachs$137.00$110.6623.80%13.07%
Nov 04, 2024Etzer DaroutBMO Capital$126.00$108.9715.63%3.99%
Sep 23, 2024Terence FlynnMorgan Stanley$145.00$113.0528.26%19.68%
Sep 17, 2024Akash TewariJefferies$150.00$123.9721.00%23.80%
Sep 16, 2024Tazeen AhmadBank of America Securities$150.00$123.4021.56%23.80%
Sep 13, 2024Akash TewariJefferies$96.00$105.00-8.57%-20.77%
Aug 06, 2024Emmanuel PapadakisDeutsche Bank$95.00$79.5019.50%-21.59%
Aug 05, 2024Terence FlynnMorgan Stanley$93.00$78.3618.68%-23.24%
Aug 02, 2024Yifeng LiuHSBC$101.00$82.0123.16%-16.64%
Jun 26, 2024Raghuram SelvarajuH.C. Wainwright$113.00$82.5236.94%-6.73%
May 13, 2024Cory KasimovEvercore ISI$100.00$92.727.85%-17.46%
May 07, 2024Etzer DaroutBMO Capital$122.00$91.5333.29%0.69%
Mar 22, 2024Yifeng LiuHSBC$90.00$91.83-1.99%-25.72%
Mar 21, 2024William MaughanCanaccord Genuity$171.00$91.9985.89%41.14%
Mar 21, 2024Etzer DaroutBMO Capital$123.00$91.9933.71%1.52%
Mar 21, 2024Chris ShibutaniGoldman Sachs$91.00$91.99-1.08%-24.89%
Jan 31, 2023Goldman Sachs$156.00$143.418.78%28.76%
Dec 02, 2022Mani ForooharLeerink Partners$81.00$169.47-52.20%-33.15%
May 17, 2022Andrew AngUBS$168.00$159.805.13%38.66%
May 10, 2022Matthew HarrisonMorgan Stanley$195.00$140.3238.97%60.94%
Apr 16, 2022Robert BurnsH.C. Wainwright$298.00$175.2970.00%145.96%
Apr 10, 2022Arlinda LeeCanaccord Genuity$300.00$170.2676.20%147.61%
Jan 21, 2022Eliana MerleUBS$170.00$147.5015.25%40.31%
Dec 22, 2021Suzanne van VoorthuizenKempen & Co$350.00$259.7034.77%188.87%
Dec 09, 2021Daina GrayboschLeerink Partners$253.00$284.21-10.98%108.81%
Oct 04, 2021Olga SmolentsevaBryan Garnier & Co Ltd$359.00$248.9044.23%196.30%

The latest BioNTech SE stock forecast, released on Nov 19, 2024 by Cory Kasimov from Evercore ISI, set a price target of $125.00, which represents a 54.70% increase from the stock price at the time of the forecast ($80.80), and a 3.17% increase from BNTX last price ($121.16).

BioNTech SE Price Target by Period

1M3M12M
# Anlaysts-418
Avg Price Target-$127.25$119.39
Last Closing Price$121.16$121.16$121.16
Upside/Downside-100.00%5.03%-1.46%

In the current month, the average price target of BioNTech SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioNTech SE's last price of $121.16. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2024Evercore ISIOutperformUpgrade
Nov 13, 2024Leerink PartnersOutperformOutperformHold
Nov 08, 2024Goldman SachsBuyBuyUpgrade
Oct 21, 2024Cowen & Co.HoldHoldHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 07, 2024UBSBuyBuyHold
Sep 23, 2024Morgan StanleyEqual-WeightOverweightUpgrade
Sep 19, 2024Deutsche BankBuyBuyHold
Sep 18, 2024UBSNeutralNeutralHold
Sep 16, 2024Cowen & Co.HoldHoldHold
Sep 16, 2024H.C. WainwrightBuyBuyHold
Sep 16, 2024Bank of America SecuritiesBuyBuyHold
Sep 13, 2024H.C. WainwrightUnderperformUnderperformHold
Sep 13, 2024JefferiesBuyBuyHold
Sep 13, 2024JefferiesHoldHoldHold
Aug 19, 2024Deutsche BankUnderperformUnderperformHold
Aug 16, 2024OppenheimerPerformPerformHold
Aug 16, 2024BMO CapitalOutperformOutperformHold
Aug 06, 2024Deutsche BankBuyUpgrade
Aug 06, 2024Cowen & Co.HoldHoldHold
Aug 01, 2024H.C. WainwrightBuyBuyHold
Jun 27, 2024William BlairMarket PerformMarket PerformHold
Jun 26, 2024H.C. WainwrightBuyBuyHold
Jun 24, 2024BMO CapitalOutperformOutperformHold
May 24, 2024UBSBuyBuyHold
May 07, 2024BMO CapitalOutperformOutperformHold
May 07, 2024Cowen & Co.HoldHoldHold
Apr 17, 2024UBSBuyBuyHold
Apr 17, 2024H.C. WainwrightUnderperformUnderperformHold
Apr 09, 2024BMO CapitalOutperformOutperformHold
Mar 21, 2024Goldman SachsBuyBuyHold
Feb 20, 2024H.C. WainwrightBuyBuyHold
Jan 23, 2024H.C. WainwrightBuyBuyHold
Dec 01, 2023J.P. MorganUnderweightDowngrade
Dec 01, 2023CitigroupUnderweightDowngrade
Nov 14, 2023Cowen & Co.BuyBuyHold
May 17, 2023Redburn PartnersBuyUpgrade
Mar 28, 2023Goldman SachsNeutralNeutralHold
Mar 28, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Mar 28, 2023Canaccord GenuityBuyBuyHold
Jan 31, 2023Goldman SachsNeutralNeutralHold
Dec 15, 2022Bank of America SecuritiesBuyUpgrade
Dec 02, 2022Argus ResearchBuyBuyHold
Aug 10, 2022WedbushBuyBuyHold
Aug 08, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 17, 2022UBSNeutralNeutralHold
May 10, 2022Morgan StanleyHoldHoldHold
Apr 15, 2022H.C. WainwrightBuyBuyHold

BioNTech SE's last stock rating was published by Evercore ISI on Nov 19, 2024. The company Upgrade its BNTX rating from "null" to "Outperform".

BioNTech SE Financial Forecast

BioNTech SE Revenue Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
Revenue------------$1.28B$4.28B$3.46B$3.20B$6.37B$5.53B$6.09B$5.31B$2.05B$345.44M$67.46M$41.76M$27.66M$28.66M
Avg Forecast$1.81B$1.26B$1.12B$202.89M$284.21M$1.12B$572.38M$144.58M$479.46M$2.03B$899.06M$685.12M$1.15B$3.91B$2.02B$4.07B$4.80B$4.45B$5.90B$3.86B$1.71B$232.24M$60.40M$95.00M$26.52M$34.04M
High Forecast$2.32B$1.61B$1.43B$260.08M$359.15M$1.26B$733.74M$185.34M$484.96M$3.01B$919.39M$878.28M$1.47B$5.78B$2.02B$4.07B$4.80B$4.45B$5.90B$3.86B$1.71B$232.24M$60.40M$95.00M$26.52M$40.84M
Low Forecast$1.37B$952.16M$847.05M$153.77M$209.24M$892.44M$433.80M$109.58M$473.96M$1.67B$878.72M$519.25M$871.81M$2.93B$2.02B$4.07B$4.80B$4.45B$5.90B$3.86B$1.71B$232.24M$60.40M$95.00M$26.52M$27.23M
# Analysts11113105648464534351010101010101020
Surprise %------------1.11%1.09%1.71%0.79%1.33%1.24%1.03%1.38%1.19%1.49%1.12%0.44%1.04%0.84%

BioNTech SE's average Quarter revenue forecast for Jun 23 based on 6 analysts is $685.12M, with a low forecast of $519.25M, and a high forecast of $878.28M. BNTX's average Quarter revenue forecast represents a -46.35% decrease compared to the company's last Quarter revenue of $1.28B (Mar 23).

BioNTech SE EBITDA Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
# Analysts11113105648464534351010101010101020
EBITDA------------$840.60M$3.36B$2.26B$1.96B$4.72B$4.74B$4.69B$4.04B$1.66B$194.28M$-177.11M$-71.94M$-44.27M$-21.09M
Avg Forecast$208.21M$144.56M$128.60M$23.35M$32.70M$128.82M$65.86M$16.64M$55.17M$233.32M$103.45M$78.84M$132.36M$449.99M$307.89M$619.29M$2.55B$677.58M$898.33M$586.82M$1.06B$35.33M$9.19M$-316.70M$4.03M$-25.14M
High Forecast$266.91M$185.32M$164.86M$29.93M$41.33M$144.50M$84.43M$21.33M$55.80M$346.55M$105.79M$101.06M$169.68M$665.30M$307.89M$619.29M$3.06B$677.58M$898.33M$586.82M$1.27B$35.33M$9.19M$-253.36M$4.03M$-20.11M
Low Forecast$157.80M$109.56M$97.47M$17.69M$24.08M$102.69M$49.92M$12.61M$54.54M$192.14M$101.11M$59.75M$100.32M$337.23M$307.89M$619.29M$2.04B$677.58M$898.33M$586.82M$844.18M$35.33M$9.19M$-380.04M$4.03M$-30.17M
Surprise %------------6.35%7.47%7.35%3.16%1.85%7.00%5.22%6.88%1.57%5.50%-19.28%0.23%-10.97%0.84%

6 analysts predict BNTX's average Quarter EBITDA for Jun 23 to be $78.84M, with a high of $101.06M and a low of $59.75M. This is -90.62% lower than BioNTech SE's previous annual EBITDA (Mar 23) of $840.60M.

BioNTech SE Net Income Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
# Analysts11113105648464534351010101010101020
Net Income------------$502.20M$2.28B$1.78B$1.67B$3.70B$3.17B$3.21B$2.79B$1.13B$366.91M$-210.03M$-88.30M$-53.39M$-30.10M
Avg Forecast$-1.18B$64.19M$89.85M$-556.32M$-440.61M$100.94M$-373.98M$-493.84M$-305.29M$582.54M$-144.69M$-203.85M$64.61M$1.89B$815.93M$1.69B$1.87B$1.77B$2.50B$1.79B$718.84M$-40.72M$-90.17M$-344.35M$-58.69M$-35.75M
High Forecast$-809.69M$87.72M$122.78M$-381.23M$-265.07M$502.78M$-256.28M$-338.41M$-209.21M$725.97M$-99.15M$-139.69M$88.29M$3.07B$815.93M$1.69B$2.24B$1.77B$2.50B$1.79B$862.61M$-40.72M$-90.17M$-275.48M$-58.69M$-28.60M
Low Forecast$-1.61B$43.99M$61.57M$-760.21M$-600.35M$-161.12M$-511.04M$-674.83M$-417.18M$432.49M$-197.72M$-278.57M$44.27M$1.28B$815.93M$1.69B$1.49B$1.77B$2.50B$1.79B$575.08M$-40.72M$-90.17M$-413.23M$-58.69M$-42.90M
Surprise %------------7.77%1.20%2.19%0.99%1.98%1.79%1.29%1.56%1.57%-9.01%2.33%0.26%0.91%0.84%

BioNTech SE's average Quarter net income forecast for Jun 23 is $-203.85M, with a range of $-278.57M to $-139.69M. BNTX's average Quarter net income forecast represents a -140.59% decrease compared to the company's last Quarter net income of $502.20M (Mar 23).

BioNTech SE SG&A Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
# Analysts11113105648464534351010101010101020
SG&A------------$131.60M$137.50M$153.80M$148.10M$105.10M$145.90M$76.90M$59.80M$47.60M$35.66M$27.59M$20.25M$15.20M$11.25M
Avg Forecast$296.62M$205.95M$183.21M$33.26M$46.59M$183.52M$93.83M$23.70M$78.60M$332.39M$147.38M$112.31M$188.57M$641.07M$331.76M$667.29M$53.05M$730.10M$967.96M$632.31M$30.33M$38.07M$9.90M$78.97M$4.35M$13.36M
High Forecast$380.24M$264.01M$234.86M$42.64M$58.88M$205.87M$120.28M$30.38M$79.50M$493.70M$150.71M$143.97M$241.73M$947.81M$331.76M$667.29M$63.66M$730.10M$967.96M$632.31M$36.40M$38.07M$9.90M$94.76M$4.35M$16.03M
Low Forecast$224.81M$156.09M$138.86M$25.21M$34.30M$146.30M$71.11M$17.96M$77.70M$273.73M$144.05M$85.12M$142.91M$480.43M$331.76M$667.29M$42.44M$730.10M$967.96M$632.31M$24.27M$38.07M$9.90M$63.17M$4.35M$10.69M
Surprise %------------0.70%0.21%0.46%0.22%1.98%0.20%0.08%0.09%1.57%0.94%2.79%0.26%3.50%0.84%

BioNTech SE's average Quarter SG&A projection for Jun 23 is $112.31M, based on 6 Wall Street analysts, with a range of $85.12M to $143.97M. The forecast indicates a -14.66% fall compared to BNTX last annual SG&A of $131.60M (Mar 23).

BioNTech SE EPS Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
# Analysts11113105648464534351010101010101020
EPS------------$2.07$9.38$7.43$6.86$15.13$12.98$13.24$11.42$4.64$1.56$-0.88$-0.38$-0.24$-0.13
Avg Forecast$-4.83$0.26$0.37$-2.27$-1.80$0.41$-1.53$-2.02$-1.25$2.38$-0.59$-0.83$0.26$7.74$3.43$7.09$9.16$7.46$10.51$7.54$2.94$-0.17$-0.38$-0.06$-0.25$-0.17
High Forecast$-3.31$0.36$0.50$-1.56$-1.08$2.06$-1.05$-1.38$-0.86$2.97$-0.41$-0.57$0.36$12.55$3.43$7.09$9.16$7.46$10.51$7.54$2.94$-0.17$-0.38$-0.06$-0.25$-0.14
Low Forecast$-6.60$0.18$0.25$-3.11$-2.45$-0.66$-2.09$-2.76$-1.71$1.77$-0.81$-1.14$0.18$5.22$3.43$7.09$9.16$7.46$10.51$7.54$2.94$-0.17$-0.38$-0.06$-0.25$-0.21
Surprise %------------7.84%1.21%2.16%0.97%1.65%1.74%1.26%1.52%1.58%-9.11%2.32%6.61%0.97%0.75%

According to 6 Wall Street analysts, BioNTech SE's projected average Quarter EPS for Jun 23 is $-0.83, with a low estimate of $-1.14 and a high estimate of $-0.57. This represents a -140.27% decrease compared to BNTX previous annual EPS of $2.07 (Mar 23).

BioNTech SE Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.18$70.0038788.89%Buy
ELEVElevation Oncology$0.62$9.001351.61%Buy
NVAXNovavax$8.81$20.33130.76%Buy
IOVAIovance Biotherapeutics$6.07$13.50122.41%Buy
CRSPCRISPR Therapeutics$41.21$77.5088.06%Buy
SRPTSarepta Therapeutics$115.45$184.0059.38%Buy
KRYSKrystal Biotech$156.30$210.3334.57%Buy
PTCTPTC Therapeutics$45.22$50.5011.68%Buy
BNTXBioNTech SE$121.16$127.785.46%Buy
MDGLMadrigal Pharmaceuticals$326.33$315.75-3.24%Buy
DNAGinkgo Bioworks$12.25$7.00-42.86%Buy

BNTX Forecast FAQ

Is BioNTech SE a good buy?

Yes, according to 18 Wall Street analysts, BioNTech SE (BNTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 77.78% of BNTX's total ratings.

What is BNTX's price target?

BioNTech SE (BNTX) average price target is $127.78 with a range of $95 to $150, implying a 5.46% from its last price of $121.16. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BioNTech SE stock go up soon?

According to Wall Street analysts' prediction for BNTX stock, the company can go up by 5.46% (from the last price of $121.16 to the average price target of $127.78), up by 23.80% based on the highest stock price target, and down by -21.59% based on the lowest stock price target.

Can BioNTech SE stock reach $200?

BNTX's average twelve months analyst stock price target of $127.78 does not support the claim that BioNTech SE can reach $200 in the near future.

What are BioNTech SE's analysts' financial forecasts?

BioNTech SE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.32B (high $2.66B, low $1.91B), average EBITDA is $266.49M (high $306.06M, low $219.75M), average net income is $-1.072B (high $-301M, low $-1.764B), average SG&A $379.65M (high $436.03M, low $313.07M), and average EPS is $-4.384 (high $-1.231, low $-7.213). BNTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.86B (high $3.66B, low $2.16B), average EBITDA is $329.21M (high $421.43M, low $248.8M), average net income is $-843M (high $-436M, low $-1.255B), average SG&A $469.01M (high $600.38M, low $354.45M), and average EPS is $-3.446 (high $-1.782, low $-5.131).

Did the BNTX's actual financial results beat the analysts' financial forecasts?

Based on BioNTech SE's last annual report (Dec 2022), the company's revenue was $17.31B, beating the average analysts forecast of $14.8B by 16.93%. Apple's EBITDA was $13.1B, beating the average prediction of $3.93B by 233.57%. The company's net income was $9.43B, beating the average estimation of $6.26B by 50.68%. Apple's SG&A was $544.2M, missing the average forecast of $1.69B by -67.86%. Lastly, the company's EPS was $38.78, beating the average prediction of $27.42 by 41.43%. In terms of the last quarterly report (Mar 2023), BioNTech SE's revenue was $1.28B, beating the average analysts' forecast of $1.15B by 11.01%. The company's EBITDA was $840.6M, beating the average prediction of $132.36M by 535.08%. BioNTech SE's net income was $502.2M, beating the average estimation of $64.61M by 677.31%. The company's SG&A was $131.6M, missing the average forecast of $188.57M by -30.21%. Lastly, the company's EPS was $2.07, beating the average prediction of $0.264 by 683.59%